Ontology highlight
ABSTRACT: Background
The Centers for Medicare & Medicaid Services considered whether to reimburse stool DNA testing for colorectal cancer screening among Medicare enrollees.Objective
To evaluate the conditions under which stool DNA testing could be cost-effective compared with the colorectal cancer screening tests currently reimbursed by the Centers for Medicare & Medicaid Services.Design
Comparative microsimulation modeling study using 2 independently developed models.Data sources
Derived from literature.Target population
A cohort of persons aged 65 years. A sensitivity analysis was also conducted, in which a cohort of persons aged 50 years was studied.Time horizon
Lifetime.Perspective
Third-party payer.Intervention
Stool DNA test every 3 or 5 years in comparison with currently recommended colorectal cancer screening strategies.Outcome measures
Life expectancy, lifetime costs, incremental cost-effectiveness ratios, and threshold costs.Results of base-case analysis
Assuming a cost of $350 per test, strategies of stool DNA testing every 3 or 5 years yielded fewer life-years and higher costs than the currently recommended colorectal cancer screening strategies. Screening with the stool DNA test would be cost-effective at a per-test cost of $40 to $60 for stool DNA testing every 3 years, depending on the simulation model used. There were no levels of sensitivity and specificity for which stool DNA testing would be cost-effective at its current cost of $350 per test. Stool DNA testing every 3 years would be cost-effective at a cost of $350 per test if the relative adherence to stool DNA testing were at least 50% better than that with other screening tests.Results of sensitivity analysis
None of the results changed substantially when a cohort of persons aged 50 years was considered.Limitation
No pathways other than the traditional adenoma-carcinoma sequence were modeled.Conclusion
Stool DNA testing could be a cost-effective alternative for colorectal cancer screening if the cost of the test substantially decreased or if its availability would entice a large fraction of otherwise unscreened persons to receive screening.
SUBMITTER: Lansdorp-Vogelaar I
PROVIDER: S-EPMC3578600 | biostudies-literature | 2010 Sep
REPOSITORIES: biostudies-literature
Lansdorp-Vogelaar Iris I Kuntz Karen M KM Knudsen Amy B AB Wilschut Janneke A JA Zauber Ann G AG van Ballegooijen Marjolein M
Annals of internal medicine 20100901 6
<h4>Background</h4>The Centers for Medicare & Medicaid Services considered whether to reimburse stool DNA testing for colorectal cancer screening among Medicare enrollees.<h4>Objective</h4>To evaluate the conditions under which stool DNA testing could be cost-effective compared with the colorectal cancer screening tests currently reimbursed by the Centers for Medicare & Medicaid Services.<h4>Design</h4>Comparative microsimulation modeling study using 2 independently developed models.<h4>Data sou ...[more]